Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 74Prostatic Neoplasms 70Neoplasms 51Multiple Myeloma 48Lung Neoplasms 40Colorectal Neoplasms 38Ovarian Neoplasms 32Leukemia, Myeloid, Acute 32Melanoma 31Lymphoma, Non-Hodgkin 31Neoplasm Metastasis 30Lymphoma 30Squamous Cell Carcinoma of Head and Neck 29Pancreatic Neoplasms 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Renal Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Endometrial Neoplasms 22Carcinoma, Hepatocellular 22Uterine Cervical Neoplasms 21Urinary Bladder Neoplasms 21Sarcoma 20Head and Neck Neoplasms 20Glioma 20Recurrence 19Stomach Neoplasms 18Lymphoma, Mantle-Cell 18Triple Negative Breast Neoplasms 17Brain Neoplasms 17

Interventions

apalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Castrate-sensitive Prostate Cancer × 30 days × Clear all
NCT05884398 2026-06-05

LIBERTAS

Janssen Research & Development, LLC

Phase 3 Active not recruiting
420 enrolled
Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡